tasipimidine
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 20, 2023 (NCT06956495)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Alpha-2a adrenergic receptorAGONIST
ADRA2A agonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cccc2c1CCOC2C1=NCCN1- Mol. weight
- 232.28 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594267 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06956495 | Phase 2 | Aug 20, 2023 | ICON, Orion Corporation |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ICON | For profit | 1 | 0 | 1 | 2023 |
| Orion Corporation | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1